Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NEUROLOGIX INC (NRGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/01/2020 GN PIMCO Energy and Tactical Credit Opportunities Fund Declares Quarterly Common Share Distributions
12/06/2019 GN PIMCO Energy and Tactical Credit Opportunities Fund Declares Special Year-End Distributions
12/02/2019 GN PIMCO Energy and Tactical Credit Opportunities Fund Declares Quarterly Common Share Distributions
03/21/2019 GN PIMCO Energy and Tactical Credit Opportunities Fund Declares Quarterly Common Share Distributions
02/16/2016 SC 13D/A Medtronic plc reports a 7.3% stake in Neurologix, Inc.
02/21/2013 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/22/2012 8-K Quarterly results
03/21/2012 8-K Form 8-K - Current report
02/16/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Limited Engagement Agreement, entered into by the Company on February 14, 2012, by and between the Company and Global Resource Partners, Inc"
02/14/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/27/2012 8-K Form 8-K - Current report
12/21/2011 8-K Form 8-K - Current report
11/30/2011 8-K Form 8-K - Current report
11/15/2011 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
10/31/2011 8-K Form 8-K - Current report
10/20/2011 DEF 14C Form DEF 14C - Other definitive information statements:
10/18/2011 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of Neurologix, Inc., filed with the Secretary of State of the State of Delaware on October 14, 2011"
10/18/2011 PRER14C Form PRER14C - Information statements
09/27/2011 SC 13D NEUROLOGIX INC reports a 6.2% stake in Neurologix, Inc.
09/27/2011 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Letter Agreement dated September 26, 2011, by and between Neurologix, Inc. and Dr. Matthew J. During"
09/27/2011 DEF 14A Form DEF 14A - Other definitive proxy statements
09/20/2011 4 ADAMS ADRIAN (CEO, CHAIRMAN OF THE BOARD) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 7,420,063 options to buy @ $0.5, valued at $3.7M
09/20/2011 3 ADAMS ADRIAN (CEO, CHAIRMAN OF THE BOARD) has filed a Form 3 on NEUROLOGIX INC/DE
09/20/2011 4 KOVEN ANDREW I (See Remarks) has filed a Form 4 on NEUROLOGIX INC/DE
Txns: Granted 4,946,709 options to buy @ $0.5, valued at $2.5M
09/20/2011 3 KOVEN ANDREW I (See Remarks) has filed a Form 3 on NEUROLOGIX INC/DE
09/20/2011 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "Amendment to Amended and Restated By-Laws of Neurologix, Inc., effective September 19, 2011",
"Executive Employment Agreement between Adrian Adams and Neurologix, Inc.",
"Executive Employment Agreement between Andrew I. Koven and Neurologix, Inc.",
"Stand-Alone Stock Option Agreement between Adrian Adams and Neurologix, Inc.",
"Stand-Alone Stock Option Agreement between Andrew I. Koven and Neurologix, Inc.",
"Press release of Neurologix, Inc."
09/15/2011 PRE 14A Form PRE 14A - Other preliminary proxy statements
08/11/2011 10-Q Quarterly Report for the period ended June 30, 2011
08/11/2011 8-K Quarterly results
Docs: "NEUROLOGIX, INC. BALANCE SHEETS June 30, 2011 December 31, 2010 ASSETS Current assets: Cash and cash equivalents $ 3,453 $ 8,055 Prepaid expenses and other current assets 319 481 Total current assets 3,772 8,536 Equipment, less accumulated depreciation of $704 and $682 at June 30, 2011 and December 31, 2010, respectively 49 71 Intangible assets, less accumulated amortization of $426 and $364 at June 30, 2011 and December 31, 2010, respectively 1,137 1,065 Other assets 5 5 Total assets $ 4,963 $ 9,677 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and accrued expenses $ 3,375 $ 2,302 Notes payable, net of discount 6,078 4,695 Total current liabilities 9,453 6,997 Derivative financial instruments, at estimated fair value – warrants 4,174 6,840 Total liabilities $..."
08/04/2011 8-K Form 8-K - Current report
06/08/2011 8-K Form 8-K - Current report
05/26/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slides related to one-year efficacy results of Neurologix, Inc’s Phase 2 trial for Parkinson’s disease (furnished pursuant to Item 7.01 of Form 8-K)",
"NEUROLOGIX PRESENTS ONE-YEAR FOLLOW-UP DATA FROM PHASE 2 STUDY OF NLX-P101 IN PARKINSON’S DISEASE AT INTERNATIONAL NEUROMODULATION SOCIETY 10th WORLD CONGRESS"
05/13/2011 8-K Submission of Matters to a Vote of Security Holders
05/13/2011 10-Q Quarterly Report for the period ended March 31, 2011
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy